Cystic Fibrosis Foundation, Bethesda, MD.
J Manag Care Spec Pharm. 2021 Feb;27(2):281-284. doi: 10.18553/jmcp.2021.27.2.281.
No funding contributed to the writing of this commentary. Both authors are employed by the Cystic Fibrosis Foundation. The Cystic Fibrosis Foundation has entered into therapeutic development award agreements and licensing agreements to assist with the development of CFTR modulators that may result in intellectual property rights, royalties, and other forms of consideration provided to CFF. Some of these agreements are subject to confidentiality restrictions and, thus, CFF cannot comment on them.
本评论文章的撰写未获得任何资金支持。两位作者均受雇于囊性纤维化基金会。囊性纤维化基金会已签订治疗开发奖励协议和许可协议，以协助开发 CFTR 调节剂，这可能导致向囊性纤维化基金会提供知识产权、版税和其他形式的对价。其中一些协议受保密限制，因此囊性纤维化基金会无法对此发表评论。
